Clinical Trial Update: Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is assessing Senl_B19 CAR-T cells for relapsed/refractory CD19+ B-cell acute lymphoblastic leukemia and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Senl_B19 CAR-T Cells

Snippet

Sponsor: Hebei Senlang Biotechnology Inc., Ltd. | Conditions: B-ALL | Phase 2 | Status: RECRUITING